Novartis Vaccines & Diagnostics, Gmbh

Leland Stanford Junior University

Novartis Ag

Elizabeth J Mieuli

Hong Yang

Weibo Wang

Savithri Ramurthy

Anu Sharma

Paul A Renhowe

Mark Knapp

Sabina Pecchi

Sharadha Subramanian

Paul Andrew Barsanti

David Duhl

Kenneth Walter Bair

Tinya Abrams

Eric J Martin

Rama Jain

Annette Olga Walter

Ryan N Constantine

Elisa Jazan

Kris Mendenhall

Nathan Brammeier

Kelly Wayman

Megan C Phillips

Vincent P Le

Kay Huh

Martin Sendzik

James Clifford Sutton

Jiong Lan

Keith Bruce Pfister

Allan S Wagman

Simon C Ng

Mika Lindvall

Marion Wiesmann

Liana Marie Lagniton

Rustum Boyce

Victoria Sung

Liana M Klivansky

William Lenahan

Susan Kaufman

Yia Xia

Paul A Wender

Adam James Schrier

Rustum S Boyce

Lars V Heumann

Liana Marie Lagnition

Rainer Kramer

Carolyn Gauntlett

Dennis Fournogerakis

Pierre-Luc Boudreault

Brian DeChristopher

Xia Yia

Mika K Lindvall

William P Lenahan

Embodiments of the present disclosure provide for prostratin analogs, bryostatin analogs, prodrugs of prostratin and prostratin analogs, methods of making prostratin analogs, and methods of making prodrugs of prostratin and prostratin analogs, methods of use of prostratin analogs, bryostatin analogs, and prodrugs thereof, and the like.

Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: 

Substituted imidazole derivates

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

Substituted imidazole derivatives

Growing community of inventors

Stanford, CA, United States of America

Elizabeth J Mieuli